BioSpace News Archive

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, announced that William Stilley, Chief Executive Officer of Adial Pharmaceuticals has been invited to present a Company overview at the 23rd Annual ICR Conference on Thursday, January 14, 2021 at 3:15pm-3:55pm Eastern Time.

The Pulmonary Fibrosis Foundation announced enrollment of the first patient in PRECISIONS clinical trial.

Growing demand for medical imaging systems such as X-ray and MRI devices is one of the key factors driving the growth of global biologic imaging reagents market.

The Center for Organ Recovery & Education announced that 2020 was the second record-breaking year in a row for Saving and Healing lives through organ, tissue and cornea donation in western Pennsylvania and West Virginia.

TraceLink Inc ., the leading digital platform company for the life sciences industry, today announced that, for the fifth consecutive year, Shabbir Dahod , president and CEO of TraceLink, will present at the 39 th Annual J.P. Morgan Healthcare Conference on Thursday, January 14 at 8:40 am EST via virtual webcast.

Increasing prevalence of infectious diseases such as HPV, HIV, influenza, hepatitis, and tuberculosis despite notable improvements in sanitation practices is the major factor expected to drive global infectious disease test device market growth during the forecast period.

Growing number of surgical procedures is primarily driving the growth of global patient temperature management devices market.

Cerus Corporation (Nasdaq: CERS) announced today preliminary product revenue for the fourth quarter and full year 2020 and provided 2021 product revenue guidance. Cerus’ unaudited preliminary product revenue for the fourth quarter of 2020 totaled $28.2 million, an increase of 35% over the $20.9 million recognized during the same period in the prior year.

New COVID-19 strain estimated to have tripled number of infections in England during November 2020 lockdown Investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Eastern Time.

MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced that the Company’s management will participate in the following investor conferences in January: